Japan has succeeded in many industries through its renowned production system. Competitive advantage, however, in the new economy is shifting from production to demand-based capabilities. One such new industry is pharmaceuticals, where Japan has been a resounding failure, both from public policy and corporate strategy perspectives. This is a detailed examination of how Japan has socially constructed its pharmaceutical industry, the economic and political bases of this construction and the consequences for corporate innovation and performance.